NEWTON, Mass., Feb. 23 (UPI) -- Pro-Pharmaceuticals said Friday it will meet with the U.S. Food and Drug Administration to discuss Davanat, a potential cancer treatment.
The company said it plans to discuss dates and plans for submitting a new drug application for Davanat at the meeting, which is scheduled for April 11. No further details about the meeting were disclosed.
Pro-Pharmaceuticals is developing Davanat as a cancer treatment that will be co-administered with 5-Fluorouracil, which is used for various cancers, including colorectal, breast and gastrointestinal.
Davanat, a carbohydrate polymer composed of mannose and galactose, appears to target specific lectin receptors known as galectins that are over-expressed on cancer cells. Pro-Pharmaceuticals said the use of Davanat may allow for higher doses of chemotherapy with no increase in toxicity.
